Elsevier

Biochimie

Volume 159, April 2019, Pages 36-48
Biochimie

Review
The n-3 docosapentaenoic acid (DPA): A new player in the n-3 long chain polyunsaturated fatty acid family

https://doi.org/10.1016/j.biochi.2019.01.022Get rights and content

Highlights

  • n-3 DPA could be considered like a dietary source of EPA tissue content.

  • No evidence showed that dietary n-3 DPA increased brain DHA.

  • Hydroxy-metabolites from n-3 DPA are involved in the pro-resolution of inflammation.

  • More and more evidences about the n-3 DPA specific effects to decrease lipid parameters.

  • n-3 DPA purification methods will allow its accessibility for further in vivo studies.

Abstract

The n-3 docosapentaenoic acid (n-3 DPA) is less studied n-3 long-chain polyunsaturated fatty acid (LCPUFA), compared to its counterparts eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). Present in food sources in non-negligible quantities, as well as in human milk, dietary n-3 DPA is of current interest both for its ability to increase EPA and DHA tissue status and for its specific or shared biological effects. Indeed, some evidence showed that dietary n-3 DPA is a source of EPA and slightly DHA in the major metabolic organs. n-3 DPA is also the precursor of a large panel of lipid mediators (protectins, resolvins, maresins, isoprostanes) principally implicated in the pro-resolution of the inflammation with specific effects compared to the other n-3 LCPUFA. Recent results showed that n-3 DPA is implied in the improvement of cardiovascular and metabolic disease risk markers, especially plasma lipid parameters, platelet aggregation, insulin sensitivity and cellular plasticity. Moreover, n-3 DPA is the most abundant n-3 LCPUFA in the brain after DHA and it could be specifically beneficial for elderly neuroprotection, and early-life development. These results led to the development of two drugs specifically containing n-3 DPA. This review summarizes the different knowledge about n-3 DPA direct and indirect sources, availability and purification methods, focusing thereafter on the recent findings showing n-3 DPA relationship with fatty acid metabolism, lipid mediators, Finally, the n-3 DPA biological and pharmacological effects are described.

Introduction

The n-3 long-chain polyunsaturated fatty acids (LCPUFA) have been widely studied and contribute to numerous beneficial effects, mainly associated with cardiovascular prevention [1], neurodevelopment, but also with the reduction of the risk of neurodegenerative diseases [2]. Indeed, these n-3 LCPUFA are involved in many processes such as the increase of membrane plasticity, the synthesis of oxygenated metabolites and the resolution of inflammation or the regulation of genes [3].

The majority of the n-3 LCPUFA studies were conducted using fish oils, composed of a mixture of three major n-3 LCPUFA: docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA) and n-3 docosapentaenoic acid (n-3 DPA). Most of the beneficial effects of fish oils have been attributed to DHA and then to EPA, for which there is growing interest in the independent and shared functions. On the other hand, the literature concerning the potential protective effects of n-3 DPA is brief because n-3 DPA represents less than one-third of each EPA and DHA in fish oils. In addition, n-3 DPA is not commercially available in sufficient quantity, with high purity (>98%) and at an affordable price to set up in vivo nutritional supplementation studies [4].

Studies about n-3 DPA have however begun to grow in recent years. n-3 DPA is indeed the second n-3 LCPUFA found in the brain (w/w), although its cerebral concentration is about 70 times lower than DHA. Moreover, the level of n-3 DPA in human milk is higher than that of EPA, similar to that of DHA and its level is more stable [5], implying a potential impact of n-3 DPA during pregnancy and development, which is the subject of a recent review [6]. While obtaining optimal tissue status in n-3 LCPUFA is one of the current public health challenges, n-3 DPA is also the only intermediate between EPA and DHA in the n-3 LCPUFA conversion pathway from α-linolenic acid (ALA) present in significant quantities in the diet. Therefore, could n-3 DPA serve as a dietary source or biological reservoir of DHA and EPA?

This paper reviews and summarizes the different knowledge about n-3 DPA and focus on the most recent findings synthesized in Table 1. To more thorough review concerning specific knowledges, the reader is encouraged to read another reviews specific about n-3 DPA or including it, as mentioned in adequate sections below [2,4,[6], [7], [8], [9], [10], [11], [12]].

Section snippets

Commercial availability

Suppliers who offer n-3 DPA> 98–99% purity cannot provide on demand enough quantities of n-3 DPA for in vivo studies at prices that are affordable for most research laboratories (supplier communications, 2017). Thus, studies focusing on n-3 DPA are often association studies in humans or in vitro studies. Most in vivo studies thus used n-3 DPA with a purity level <98% which therefore also contains mainly DHA, EPA and n-6 DPA, limiting the interpretation of these findings [8,9,13]. In addition,

A reservoir of EPA and DHA

n-3 DPA is the direct intermediate between EPA and DHA, in the conversion pathway from ALA, to be present in significant amounts in the human diet compared to the C24:5 n-3 and C24:6 n-3 derivatives [39]. This conversion pathway is well known and involves a sequence of desaturase enzymes adding one double bond to the carbon chain and elongase enzymes extending the carbon-chain of two carbons (Fig. 1). The n-3 LCPUFA conversion pathway is parallel to that of n-6 LCPUFA using the same sequence

Inflammation and cancer

The decrease in inflammation associated with n-3 DPA seems to come mainly from these lipid mediators, and mainly the specialized pro-resolving mediator (SPM) (maresins, protectins, resolvins). Indeed, incubation of human macrophages with Protectin D1n-3 DPA increased the monocyte differentiation, the phagocytic activity of macrophages and the apoptosis of neutrophils, which are key factors in the resolution of inflammation [71,76]. Moreover, the incubation of n-3 DPA-derived Maresin1n-3 DPA

Conclusion and prospects

An increasing number of association studies support the hypothesis that n-3 DPA is a bioactive fatty acid beneficial to human health. The suggested mechanisms involve the importance of n-3 DPA-derived lipid metabolites in the pro-resolution of inflammation in various models and mainly the importance of protectin D1 and resolvin D5 found in humans. Many other n-3 DPA-derived metabolites have also recently been identified and their potential physiological effects are not yet known. Likewise,

Declaration of interest

None.

Funding source

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Acknowledgments

We thank Pr. Thierry Durand (Institute of Biomolecules Max Mousseron, Montpellier, France) for the design of isoprostanes, Daniel Catheline (Laboratory of Biochemistry and Human Nutrition, Agrocampus Ouest, Rennes, France) for his help in the figure realization and Agrocampus Ouest, Rennes, France for funding.

References (129)

  • H.O. Bang et al.

    The composition of the Eskimo food in north Western Greenland

    Am. J. Clin. Nutr.

    (1980)
  • J.M. Curtis et al.

    Analysis of omega-3 fatty acids in foods and supplements

  • P.G. Toral et al.

    In vitro ruminal biohydrogenation of eicosapentaenoic (EPA), docosapentaenoic (DPA), and docosahexaenoic acid (DHA) in cows and ewes: intermediate metabolites and pathways

    J. Dairy Sci.

    (2018)
  • P. Howe et al.

    Dietary intake of long-chain ω-3 polyunsaturated fatty acids: contribution of meat sources

    Nutrition

    (2006)
  • K. Kuhnt et al.

    Dietary Echium oil increases long-chain n-3 PUFAs, including docosapentaenoic acid, in blood fractions and alters biochemical markers for cardiovascular disease independently of age, sex, and metabolic syndrome

    J. Nutr.

    (2014)
  • K.D. Stark et al.

    Global survey of the omega-3 fatty acids, docosahexaenoic acid and eicosapentaenoic acid in the blood stream of healthy adults

    Prog. Lipid Res.

    (2016)
  • D. Bibus et al.

    Balancing proportions of competing omega-3 and omega-6 highly unsaturated fatty acids (HUFA) in tissue lipids

    Prostaglandins Leukot. Essent. Fatty Acids

    (2015)
  • W.S. Harris et al.

    The Omega-3 Index: a new risk factor for death from coronary heart disease?

    Prev. Med.

    (2004)
  • W.S. Harris et al.

    The Omega-3 Index and relative risk for coronary heart disease mortality: estimation from 10 cohort studies

    Atherosclerosis

    (2017)
  • M.K. Gregory et al.

    Molecular basis for differential elongation of omega-3 docosapentaenoic acid by the rat Elovl5 and Elovl2

    J. Lipid Res.

    (2013)
  • F. Achard et al.

    Interconversions and distinct metabolic fate of eicosapentaenoic, docosapentaenoic and docosahexaenoic acids in bovine aortic endothelial cells

    Biochim. Biophys. Acta Lipids Lipid Metab.

    (1995)
  • T. Kanayasu-Toyoda et al.

    Docosapentaenoic acid (22:5, n-3), an elongation metabolite of eicosapentaenoic acid (20:5, n-3), is a potent stimulator of endothelial cell migration on pretreatment in vitro

    Prostaglandins Leukot. Essent. Fatty Acids

    (1996)
  • G. Kaur et al.

    Docosapentaenoic acid (22:5n-3) down-regulates the expression of genes involved in fat synthesis in liver cells, Prostaglandins Leukot

    Essent. Fat. Acids.

    (2011)
  • A. Pawar et al.

    Unsaturated fatty acid regulation of peroxisome proliferator-activated receptor ?? activity in rat primary hepatoctes

    J. Biol. Chem.

    (2003)
  • S. Ghasemi Fard et al.

    Comparison of the bioavailability of docosapentaenoic acid (DPA, 22:5N-3) and eicosapentaenoic acid (EPA, 20:5n-3) in the rat

    Prostaglandins Leukot. Essent. Fatty Acids

    (2014)
  • T.O. Akanbi et al.

    Pancreatic lipase selectively hydrolyses DPA over EPA and DHA due to location of double bonds in the fatty acid rather than regioselectivity

    Food Chem.

    (2014)
  • T.V. Hansen et al.

    The novel lipid mediator PD1n-3 DPA: an overview of the structural elucidation, synthesis, biosynthesis and bioactions

    Prostag. Other Lipid Mediat.

    (2017)
  • K.G. Primdahl et al.

    Stereocontrolled synthesis and investigation of the biosynthetic transformations of 16(: S),17(S)-epoxy-PDn-3 DPA

    Org. Biomol. Chem.

    (2017)
  • B. Dangi et al.

    Biogenic synthesis, purification, and chemical characterization of anti-inflammatory resolvins derived from docosapentaenoic acid (DPAn-6)

    J. Biol. Chem.

    (2009)
  • O. Kuda

    Bioactive metabolites of docosahexaenoic acid

    Biochimie

    (2017)
  • C.N. Serhan et al.

    Protectins and maresins: new pro-resolving families of mediators in acute inflammation and resolution bioactive metabolome

    Biochim. Biophys. Acta Mol. Cell Biol. Lipids

    (2015)
  • A. Dupuy et al.

    Simultaneous quantitative profiling of 20 isoprostanoids from omega-3 and omega-6 polyunsaturated fatty acids by LC-MS/MS in various biological samples

    Anal. Chim. Acta

    (2016)
  • P. Le Faouder et al.

    LC-MS/MS method for rapid and concomitant quantification of pro-inflammatory and pro-resolving polyunsaturated fatty acid metabolites

    J. Chromatogr. B Anal. Technol. Biomed. Life Sci.

    (2013)
  • I. De las Heras-Gómez et al.

    Potential applications of lipid peroxidation products – F4-neuroprostanes, F3-neuroprostanesn-6 DPA, F2-dihomo-isoprostanes and F2-isoprostanes - in the evaluation of the allograft function in renal transplantation

    Free Radic. Biol. Med.

    (2017)
  • C.N. Serhan

    Discovery of specialized pro-resolving mediators marks the dawn of resolution physiology and pharmacology

    Mol. Aspect. Med.

    (2017)
  • C. Morin et al.

    Anti-proliferative effects of a new docosapentaenoic acid monoacylglyceride in colorectal carcinoma cells

    Prostaglandins Leukot. Essent. Fatty Acids

    (2013)
  • E. Kishida et al.

    Docosahexaenoic acid enrichment can reduce L929 cell necrosis induced by tumor necrosis factor

    Biochim. Biophys. Acta Mol. Cell Biol. Lipids

    (2006)
  • M. Tsuji et al.
    (2003)
  • J.K. Innes et al.

    The differential effects of eicosapentaenoic acid and docosahexaenoic acid on cardiometabolic risk factors: a systematic review

    Int. J. Mol. Sci.

    (2018)
  • S.C. Dyall

    Long-chain omega-3 fatty acids and the brain: a review of the independent and shared effects of EPA, DPA and DHA

    Front. Aging Neurosci.

    (2015)
  • O.A. Byelashov et al.

    Dietary sources, current intakes, and nutritional role of omega-3 docosapentaenoic acid

    Lipid Technol.

    (2015)
  • B. Delplanque et al.

    Lipid quality in infant nutrition: current knowledge and future opportunities

    J. Pediatr. Gastroenterol. Nutr.

    (2015)
  • J. Li et al.

    The role of Omega-3 docosapentaenoic acid in pregnancy and early development

    Eur. J. Lipid Sci. Technol.

    (2016)
  • P.G. Yazdi

    A Review of the Biologic and Pharmacologic Role of Docosapentaenoic Acid N-3, F1000Research

    (2014)
  • G. Kaur et al.

    Short update on docosapentaenoic acid: a bioactive long-chain n-3 fatty acid

    Curr. Opin. Clin. Nutr. Metab. Care

    (2016)
  • X. fei Guo et al.

    Differential effects of EPA, DPA and DHA on cardio-metabolic risk factors in high-fat diet fed mice

    Prostaglandins Leukot. Essent. Fatty Acids

    (2017)
  • G. Kaur et al.

    Orally administered [14C]DPA and [14C]DHA are metabolised differently to [14C]EPA in rats

    Br. J. Nutr.

    (2013)
  • R.A. Alvarez et al.

    Docosapentaenoic acid is converted to docosahexaenoic acid in the retinas of normal and prcd-affected miniature poodle dogs

    Investig. Ophthalmol. Vis. Sci.

    (1994)
  • R. Yamamura et al.

    Industrial high-performance liquid chromatography purification of docosahexaenoic acid ethyl ester and docosapentaenoic acid ethyl ester from single-cell oil

    J. Am. Oil Chem. Soc.

    (1997)
  • H. Mu et al.

    Combined urea complexation and argentated silica gel column chromatography for concentration and separation of PUFAs from tuna oil: based on improved DPA level

    JAOCS, J. Am. Oil Chem. Soc.

    (2016)
  • Cited by (0)

    View full text